Eliasson and Kenna (1996) reported that anti-CYP2E1 antibody levels in sera from patients with halothane hepatitis were higher than in halothane-tolerant controls, healthy controls, patients with primary biliary cirrhosis, and other liver diseases, directly proving evidence that halothane hepatitis is a CYP2E1-mediated autoimmune disease. The gene discussed is CYP2E1; the disease is liver disorder.